Inhibition of hepatitis B virus DNA replication by a thermostable interferon-γ variant

Antiviral Therapy

Volumn 15, Issue 6, 2010, Pages 861-869

  Brunelle, Marie Noëlle ^a,b,c   Saboulard, Didier ^d   Massinet, Hélène ^a,b,c   Lamant, Céline ^a,b,c   Soussan, Patrick ^a,b,c   Brezillon, Nicolas ^a,b,c   Kremsdorf, Dina ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT PASTEUR   (France)

^d Parc Scientifique de Luminy   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; LUCIFERASE; RECOMBINANT GAMMA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DNA REPLICATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN VARIANT; SIGNAL TRANSDUCTION; THERMOSTABILITY; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; DNA REPLICATION; DNA, VIRAL; FEMALE; HALF-LIFE; HELA CELLS; HEP G2 CELLS; HEPATITIS B VIRUS; HUMANS; INTERFERON-GAMMA, RECOMBINANT; MICE; MICE, INBRED C57BL; VIRUS REPLICATION;

EID: 77957347769     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1639     Document Type: Article

References (45)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-1745.
2. Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 2009; 286:52-59.
3. Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009; 49 Suppl 5:S13-S21.
4. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009; 49 Suppl 5:S103-S111.
5. Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2009; 49 Suppl 5:S112-S121.
6. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48 Suppl 1:S2-S19.
7. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131:1253-1261.
8. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19:65-91.
9. Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A 2005; 102:9913-9917.
10. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75:163-189.
11. Robek MD, Wieland SF, Chisari FV. Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol 2002; 76:3570-3574.
12. Parvez MK, Sehgal D, Sarin SK, Basir SF, Jameel S. Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma. World J Gastroenterol 2006; 12:3006-3014.
13. Park SG, Ryu HM, Lim SO, et al. Interferon-gamma inhibits hepatitis B virus-induced NF-kappaB activation through nuclear localization of NF-kappaB-inducing kinase. Gastroenterology 2005; 128:2042-2053.
14. Guidotti LG, Ishikawa T, Hobbs MV, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4:25-36.
15. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004; 101:6669-6674.
16. Dumortier J, Schonig K, Oberwinkler H, et al. Liver-specific expression of interferon gamma following adenoviral gene transfer controls hepatitis B virus replication in mice. Gene Ther 2005; 12:668-677.
17. Klocker U, Schultz U, Schaller H, Protzer U. Endotoxin stimulates liver macrophages to release mediators that inhibit an early step in hepadnavirus replication. J Virol 2000; 74:5525-5533.
18. Uprichard SL, Wieland SF, Althage A, Chisari FV. Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc Natl Acad Sci U S A 2003; 100:1310-1315.
19. Kakumu S, Ishikawa T, Mizokami M, et al. Treatment with human gamma interferon of chronic hepatitis B: comparative study with alpha interferon. J Med Virol 1991; 35:32-37.
20. Marcellin P, Loriot MA, Boyer N, et al. Recombinant human gamma-interferon in patients with chronic active hepatitis B: pharmacokinetics, tolerance and biological effects. Hepatology 1990; 12:155-158.
21. Carreno V, Moreno A, Galiana F, Bartolome FJ. Alpha- and gamma-interferon versus alpha-interferon alone in chronic hepatitis B. A randomized controlled study. J Hepatol 1993; 17:321-325.
22. Musch E, Hogemann B, Gerritzen A, et al. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B. Hepatogastroenterology 1998; 45:2282-2294.
23. Goossens K, Haelewyn J, Meersman F, De Ley M, Heremans K. Pressure- and temperature-induced unfolding and aggregation of recombinant human interferon-gamma: a Fourier transform infrared spectroscopy study. Biochem J 2003; 370:529-535.
24. Haelewyn J, Michiels L, Verhaert P, et al. Interaction of truncated human interferon gamma variants with the interferon gamma receptor: crucial importance of Arg-129. Biochem J 1997; 324:591-595.
25. Bumelis VA, Bumeliene Z, Gedminiene G, et al. Investigation of thermal stability of recombinant human interferon-gamma. Biologija (Vilnius) 2002; 2:37-41.
26. Matsumura M, Aiba S. Screening for thermostable mutant of kanamycin nucleotidyltransferase by the use of a transformation system for a thermophile, Bacillus stearothermophilus. J Biol Chem 1985; 260:15298-15303.
27. Hoseki J, Yano T, Koyama Y, Kuramitsu S, Kagamiyama H. Directed evolution of thermostable kanamycin-resistance gene: a convenient selection marker for Thermus thermophilus. J Biochem 1999; 126:951-956.
28. Delcourt M, inventor; Biométhodes, assignee. Method for selecting stable proteins in non-standard physicochemical conditions (THR). French patent FR2886943/WO 2006/134240 A1. 10 June 2005.
29. Delcourt M, Blesa S, inventors; Biométhodes, assignee. Method for massive mutagenesis. European patent 1311670 B1/US patent 7202086 B2 2001. 25 August 2000.
30. Saboulard D, Dugas V, Jaber M, et al. High-throughput site-directed mutagenesis using oligonucleotides synthesized on DNA chips. Biotechniques 2005; 39:363-368.
31. Sells MA, Chen M-L, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepetitis B virus DNA. Proc Natl Acad Sci U S A 1987; 84:1005-1009.
32. Chautard H, Blas-Galindo E, Menguy T, et al. An activity-independent selection system of thermostable protein variants. Nat Methods 2007; 4:919-921.
33. Durantel D, Carrouee-Durantel S, Werle-Lapostolle B, et al. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology 2004; 40:855-864.
34. Soussan P, Pol J, Garreau F, et al. Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease. J Infect Dis 2008; 198:218-225.
35. Sethuraman N, Stadheim TA. Challenges in therapeutic glycoprotein production. Curr Opin Biotechnol 2006; 17:341-346.
36. Shi H, Guan SH. Increased apoptosis in HepG2.2.15 cells with hepatitis B virus expression by synergistic induction of interferon-gamma and tumour necrosis factor-alpha. Liver Int 2009; 29:349-355.
37. Rockey DC. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 2008; 12:939-962.
38. Weng HL, Wang BE, Jia JD, et al. Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol 2005; 3:819-828.
39. Brown TD, Koeller J, Beougher K, et al. A Phase I clinical trial of recombinant DNA gamma interferon. J Clin Oncol 1987; 5:790-798. (Pubitemid 17120257)
40. Gray PW, Goeddel DV. Structure of the human immune interferon gene. Nature 1982; 298:859-863.
41. Pechenov SE, Tikhonov RV, Shingarova LN, et al. Methods for preparation of recombinant cytokine proteins V. mutant analogues of human interferon-gamma with higher stability and activity. Protein Expr Purif 2002; 24:173-180.
42. Gray PW, Goeddel DV. Cloning and expression of murine immune interferon cDNA. Proc Natl Acad Sci U S A 1983; 80:5842-5846.
43. Heise T, Guidotti LG, Chisari FV. La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA. J Virol 1999; 73:5767-5776.
44. Guidotti LG, McClary H, Loudis JM, Chisari FV. Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice. J Exp Med 2000; 191:1247-1252. (Pubitemid 30207687)
45. Proto S, Taylor JA, Chokshi S, Navaratnam N, Naoumov NV. APOBEC and iNOS are not the main intracellular effectors of IFN-gamma-mediated inactivation of Hepatitis B virus replication. Antiviral Res 2008; 78:260-267.